PDF herunterladen
CC BY-NC-ND 4.0 · Gesundheitswesen 2025; 87(01): 27-37
DOI: 10.1055/a-2320-2859
Konsensstatement

Früherkennung von Typ-1-Diabetes durch Inselautoantikörper-Screening – ein Positionspapier der Fr1daPlex-Projektleiter und -Schulungszentren, des BVKJ Bayern und PaedNetz Bayern e.V.

Early Detection Of Type 1 Diabetes By Islet Autoantibody Screening: A Position Paper Of The Fr1daplex Project Leaders And Training Centres, Bvkj Bavaria And Paednetz (Registered) Bavaria
Peter Achenbach
1   Institut für Diabetesforschung, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg, Germany
2   Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München Fakultät für Medizin, Munchen, Germany
,
Reinhard Berner
3   Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Kinder- und Jugendmedizin, Technische Universität Dresden, Dresden, Germany
,
Ezio Bonifacio
4   Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany
,
Susanne Brämswig
5   Klinik für Kinder- und Jugendmedizin, RoMed Klinikum Rosenheim, Rosenheim, Germany
,
Sonja Braig
6   Klinik für Kinder und Jugendliche, Klinikum Bayreuth GmbH, Bayreuth, Germany
,
Desiree Dunstheimer
7   Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Augsburg, Augsburg, Germany
,
Uwe Ermer
8   Kinder- und Jugendmedizin, Ameos Klinikum St. Elisabeth Neuburg, Neuburg an der Donau, Germany
,
Dominik Ewald
9   Bahnhofstr. 24, Kinderarztpraxis, Regensburg, Germany
,
Gita Gemulla
3   Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Kinder- und Jugendmedizin, Technische Universität Dresden, Dresden, Germany
4   Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany
,
Julia Hauer
10   Zentrum für Kinder und Jugendmedizin, München Klinik und Klinikum rechts der Isar, Technische Universität München Fakultät für Medizin, Munchen, Germany
,
Florian Haupt
1   Institut für Diabetesforschung, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg, Germany
2   Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München Fakultät für Medizin, Munchen, Germany
,
Gabi Haus
11   Hans-Mielich-Str. 35, Kinderarztpraxis, München, Germany
,
Michael Hubmann
12   Steinweg 6, Kinderarztpraxis, Zirndorf, Germany
,
Sandra Hummel
1   Institut für Diabetesforschung, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg, Germany
2   Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München Fakultät für Medizin, Munchen, Germany
,
Michael Kandler
13   Ottilienstr. 1, Kinderarztpraxis, Regensburg, Germany
,
Olga Kordonouri
14   Diabetologie, Endokrinologie und Allgemeine Pädiatrie, Kinder- und Jugendkrankenhaus AUF DER BULT, Hannover, Germany
,
Karin Lange
15   Medizinische Psychologie, Medizinische Hochschule Hannover, Hannover, Germany
,
Otto Laub
16   Happinger Str. 98, Kinderarztpraxis, Rosenheim, Germany
,
Anja Lorrmann
17   Kinder und Jugendmedizin, KJF Klinik Josefinum GmbH, Augsburg, Germany
,
Nicole Nellen-Hellmuth
18   Kinderdiabetologie, MVZ Leopoldina GmbH, Schweinfurt, Germany
,
Marina Sindichakis
19   Klinik für Kinder- und Jugendmedizin, Kinderdiabetologie, Klinikum Traunstein, Traunstein, Germany
,
Thekla von dem Berge
14   Diabetologie, Endokrinologie und Allgemeine Pädiatrie, Kinder- und Jugendkrankenhaus AUF DER BULT, Hannover, Germany
,
Katharina Warncke
10   Zentrum für Kinder und Jugendmedizin, München Klinik und Klinikum rechts der Isar, Technische Universität München Fakultät für Medizin, Munchen, Germany
,
Leonie Weber
20   Klinik für Kinderheilkunde und Jugendmedizin, Kinderdiabetologie, Klinikum Kempten-Oberallgau GmbH, Kempten, Germany
,
Christiane Winkler
1   Institut für Diabetesforschung, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg, Germany
2   Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München Fakultät für Medizin, Munchen, Germany
,
Philip Wintermeyer
21   Ingolstädterstr. 166, Kinderarztpraxis, München, Germany
,
Anette-Gabriele Ziegler
22   Institute of Diabetes Research, Helmholtz Center Munich German Research Center for Environmental Health, Neuherberg, Germany
2   Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München Fakultät für Medizin, Munchen, Germany
› Institutsangaben Fundref Information Deutsche Diabetes-Stiftung — Bayerisches Staatsministerium für Gesundheit und Pflege — Gesund.Leben.Bayern, LP00228 Bundesministerium für Bildung und Forschung — http://dx.doi.org/10.13039/501100002347; FKZ01KX1818 LifeScience Stiftung — HMGU 2014.01, HMGU 2016.01 The Leona M. and Harry B. Helmsley Charitable Trust — G-1911–03274, G-2112–04887, G-2103–05017 JDRF International — 1-SRA-2014–310-M-R, 3-SRA-2015–72-M-R, 3-SRA-2019- Deutscher Diabetiker-Bund — B. Braun-Stiftung — http://dx.doi.org/10.13039/100010345; BBST-D-15–00016 Landesverband Bayern der Betriebskrankenkassen — Deutsches Zentrum für Diabetesforschung (DZD e.V.) — Deutsche Diabetes-Hilfe —
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Dieses Positionspapier basiert auf der langjährigen klinischen Erfahrung und grundlagen-wissenschaftlichen Forschung der Autoren zur Diagnose und Behandlung von Kindern und Jugendlichen mit einem präsymptomatischen Frühstadium des Typ-1-Diabetes. Der Nutzen sowie potenzielle Nachteile der Früherkennung von Typ-1-Diabetes durch ein Inselautoantikörper-Screening werden kritisch diskutiert. Zudem werden die Perspektiven einer Verzögerung des Ausbruchs der klinischen Stoffwechselerkrankung durch eine Teplizumab-Behandlung adressiert. Wir sehen heute die Chance einer relevanten Verbesserung der therapeutischen Möglichkeiten und der Lebensperspektive betroffener Kinder und Jugendlicher. Wichtige nächste Schritte für die Implementierung eines Inselautoantikörper-Screenings in Deutschland sind die Fortbildung der Kinder- und Jugendärzte, die über das Screening aufklären sollen, die Etablierung von wenigen überregionalen Laboratorien, die die Testung durchführen, und die Ausweitung regionaler Kapazitäten für Schulung und Betreuung der Kinder mit einem Frühstadium des Typ-1-Diabetes.

Abstract

This position paper is based on the authors' many years of clinical experience and basic science research on the diagnosis and treatment of children and adolescents with a presymptomatic early stage of type 1 diabetes. The benefits as well as potential disadvantages of early detection of type 1 diabetes by islet autoantibody screening are critically discussed. In addition, the perspectives of delaying the onset of the clinical metabolic disease through treatment with teplizumab are addressed. Today, we see the chance for a relevant improvement in therapeutic options and life perspectives of affected children and adolescents. Important next steps for the implementation of islet autoantibody screening in Germany are the training of pediatricians who should inform families about the screening, establishment of a few transregional laboratories that carry out the test, and expansion of regional capacities for the training and care of children with an early stage of type 1 diabetes.

Schlüsselwörter

Typ-1-Diabetes - Früherkennung bei Kindern - präsymptomatisches Frühstadium - Inselautoantikörper-Screening

Keywords

type 1 diabetes - early detection in children - presymptomatic early stage - islet autoantibody screening

Zusätzliches Material



Publikationsverlauf

Accepted Manuscript online:
06. Mai 2024

Artikel online veröffentlicht:
29. Juli 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Kamrath C, Rosenbauer J, Eckert AJ. et al. Incidence of Type 1 Diabetes in Children and Adolescents During the COVID-19 Pandemic in Germany: Results From the DPV Registry. Diabetes Care 2022; 45: 1762-1771
    CrossrefPubMedSuche in Google Scholar
  • 2 Norris JM, Johnson RK, Stene LC. Type 1 diabetes-early life origins and changing epidemiology. Lancet Diabetes Endocrinol 2020; 8: 226-238
    CrossrefPubMedSuche in Google Scholar
  • 3 Patterson CC, Karuranga S, Salpea P. et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019; 157: 107842
    CrossrefPubMedSuche in Google Scholar
  • 4 Kamrath C, Monkemoller K, Biester T. et al. Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic in Germany. JAMA 2020; 324: 801-804
    CrossrefPubMedSuche in Google Scholar
  • 5 Birkebaek NH, Kamrath C, Grimsmann JM. et al. Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries. Lancet Diabetes Endocrinol 2022; 10: 786-794
    CrossrefPubMedSuche in Google Scholar
  • 6 Alonso GT, Coakley A, Pyle L. et al. Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Colorado Children, 2010-2017. Diabetes Care 2020; 43: 117-121
    CrossrefPubMedSuche in Google Scholar
  • 7 Rawshani A, Sattar N, Franzen S. et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 2018; 392: 477-486
    CrossrefPubMedSuche in Google Scholar
  • 8 Karges B, Prinz N, Placzek K. et al. A Comparison of Familial and Sporadic Type 1 Diabetes Among Young Patients. Diabetes Care 2021; 44: 1116-1124
    CrossrefPubMedSuche in Google Scholar
  • 9 Barker JM, Goehrig SH, Barriga K. et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 2004; 27: 1399-1404
    CrossrefPubMedSuche in Google Scholar
  • 10 Elding Larsson H, Vehik K, Bell R. et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care 2011; 34: 2347-2352
    CrossrefPubMedSuche in Google Scholar
  • 11 Winkler C, Schober E, Ziegler AG. et al. Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. Pediatr Diabetes 2012; 13: 308-313
    CrossrefPubMedSuche in Google Scholar
  • 12 Jacobsen LM, Vehik K, Veijola R. et al. Heterogeneity of DKA Incidence and Age-Specific Clinical Characteristics in Children Diagnosed With Type 1 Diabetes in the TEDDY Study. Diabetes Care 2022; 45: 624-633
    CrossrefPubMedSuche in Google Scholar
  • 13 Wentworth JM, Oakey H, Craig ME. et al. Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in Australia and New Zealand. Pediatr Diabetes 2022; 23: 1594-1601
    CrossrefPubMedSuche in Google Scholar
  • 14 Hekkala AM, Ilonen J, Toppari J. et al. Ketoacidosis at diagnosis of type 1 diabetes: Effect of prospective studies with newborn genetic screening and follow up of risk children. Pediatr Diabetes 2018; 19: 314-319
    CrossrefPubMedSuche in Google Scholar
  • 15 Ziegler AG, Kick K, Bonifacio E. et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA 2020; 323: 339-351
    CrossrefPubMedSuche in Google Scholar
  • 16 Hummel S, Carl J, Friedl N. et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia 2023; 66: 1633-1642
    CrossrefPubMedSuche in Google Scholar
  • 17 Spiekerkötter U, Krude H. Target diseases for neonatal screening in Germany – challenges for treatment and long-term care. Dtsch Arztebl Int 2022; 119: 306-316
    CrossrefPubMedSuche in Google Scholar
  • 18 Sassmann H, Kim-Dorner SJ, Berndt V. et al. Understanding Daily, Emotional, and Physical Burdens and Needs of Parents Caring for Children with Type 1 Diabetes. J Diabetes Res 2022; 2022: 9604115
    CrossrefPubMedSuche in Google Scholar
  • 19 Lachin JM, Bebu I, Nathan DM. et al. The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. Diabetes Care 2021; 44: 2225-2230
    CrossrefPubMedSuche in Google Scholar
  • 20 de Wit M, Gajewska KA, Goethals ER. et al. ISPAD Clinical Practice Consensus Guidelines 2022: Psychological care of children, adolescents and young adults with diabetes. Pediatr Diabetes 2022; 23: 1373-1389
    CrossrefPubMedSuche in Google Scholar
  • 21 Cameron FJ, Scratch SE, Nadebaum C. et al. Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. Diabetes Care 2014; 37: 1554-1562
    CrossrefPubMedSuche in Google Scholar
  • 22 Insel RA, Dunne JL, Atkinson MA. et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015; 38: 1964-1974
    CrossrefPubMedSuche in Google Scholar
  • 23 American Diabetes Association. Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45: S17-S38
    CrossrefPubMedSuche in Google Scholar
  • 24 Besser REJ, Bell KJ, Couper JJ. et al. ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. Pediatr Diabetes 2022; 23: 1175-1187
    CrossrefPubMedSuche in Google Scholar
  • 25 Landgraf R, Heinemann L, Schleicher E. et al. Definition, classification, diagnostics and differential diagnostics of diabetes mellitus: update 2022. Diabetol Stoffwechs 2022; 17: S98-S110
    Thieme ConnectPubMedSuche in Google Scholar
  • 26 Weiss A, Zapardiel-Gonzalo J, Voss F. et al. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia 2022; 65: 2121-2131
    CrossrefPubMedSuche in Google Scholar
  • 27 Raab J, Haupt F, Scholz M. et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open 2016; 6: e011144
    CrossrefPubMedSuche in Google Scholar
  • 28 Amoroso M, Achenbach P, Powell M. et al. 3 Screen islet cell autoantibody ELISA: A sensitive and specific ELISA for the combined measurement of autoantibodies to GAD(65), to IA-2 and to ZnT8. Clin Chim Acta 2016; 462: 60-64
    CrossrefPubMedSuche in Google Scholar
  • 29 Ziegler AG, Haupt F, Scholz M. et al. 3 Screen ELISA for High-Throughput Detection of Beta Cell Autoantibodies in Capillary Blood. Diabetes Technol Ther 2016; 18: 687-693
    CrossrefPubMedSuche in Google Scholar
  • 30 Bonifacio E, Weiss A, Winkler C. et al. An Age-Related Exponential Decline in the Risk of Multiple Islet Autoantibody Seroconversion During Childhood. Diabetes Care 2021; 44: 2260-2268
    CrossrefPubMedSuche in Google Scholar
  • 31 Ghalwash M, Dunne JL, Lundgren M. et al. Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 2022; 10: 589-596
    CrossrefPubMedSuche in Google Scholar
  • 32 Ziegler AG, Rewers M, Simell O. et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309: 2473-2479
    CrossrefPubMedSuche in Google Scholar
  • 33 Vehik K, Lynch KF, Schatz DA. et al. Reversion of beta-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study. Diabetes Care 2016; 39: 1535-1542
    CrossrefPubMedSuche in Google Scholar
  • 34 Miller KM, Foster NC, Beck RW. et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015; 38: 971-978
    CrossrefPubMedSuche in Google Scholar
  • 35 Dehn-Hindenberg A, Sassmann H, Berndt V. et al. Long-term Occupational Consequences for Families of Children With Type 1 Diabetes: The Mothers Take the Burden. Diabetes Care 2021; 44: 2656-2663
    CrossrefPubMedSuche in Google Scholar
  • 36 Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit. Gesundheit der Vorschulkinder in Bayern: Ergebnisse der Schuleingangsuntersuchung zum Schuljahr 2014/2015 https://www.lgl.bayern.de/publikationen/gesundheit/doc/schuleingangsuntersuchung_2014_2015.pdf Published August 2017. Accessed December 30, 2019.
    PubMed
  • 37 Karges B, Neu A, Hofer SE. et al. [Frequency and influencing factors of ketoacidosis at diabetes onset in children and adolescents--a long-term study between 1995 and 2009]. Klin Padiatr 2011; 223: 70-73
    Thieme ConnectPubMedSuche in Google Scholar
  • 38 Segerer H, Wurm M, Grimsmann JM. et al. Diabetic Ketoacidosis at Manifestation of Type 1 Diabetes in Childhood and Adolescence-Incidence and Risk Factors. Dtsch Arztebl Int 2021; 118: 367-372
    CrossrefPubMedSuche in Google Scholar
  • 39 Duca LM, Wang B, Rewers M. et al. Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control. Diabetes Care 2017; 40: 1249-1255
    CrossrefPubMedSuche in Google Scholar
  • 40 Fredheim S, Johannesen J, Johansen A. et al. Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA1c levels. Diabetologia 2013; 56: 995-1003
    CrossrefPubMedSuche in Google Scholar
  • 41 Duca LM, Reboussin BA, Pihoker C. et al. Diabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: The SEARCH for diabetes in youth study. Pediatr Diabetes 2019; 20: 172-179
    CrossrefPubMedSuche in Google Scholar
  • 42 Lundgren M, Jonsdottir B, Elding Larsson H. et al. Effect of screening for type 1 diabetes on early metabolic control: the DiPiS study. Diabetologia 2019; 62: 53-57
    CrossrefPubMedSuche in Google Scholar
  • 43 Ghetti S, Kuppermann N, Rewers A. et al. Cognitive Function Following Diabetic Ketoacidosis in Children With New-Onset or Previously Diagnosed Type 1 Diabetes. Diabetes Care 2020; 43: 2768-2775
    CrossrefPubMedSuche in Google Scholar
  • 44 Ghetti S, Kuppermann N, Rewers A. et al. Cognitive function following diabetic ketoacidosis in young children with type 1 diabetes. Endocrinol Diabetes Metab 2023; 6: e412
    CrossrefPubMedSuche in Google Scholar
  • 45 Hummel S, Friedl N, Winkler C. et al. Presymptomatic type 1 diabetes and disease severity at onset. Reply to Schneider J, Gemulla G, Bonifacio E et al. Diabetologia 2023; 66: 2389-2390
    CrossrefPubMedSuche in Google Scholar
  • 46 Schneider J, Gemulla G, Kiess W. et al. Presymptomatic type 1 diabetes and disease severity at onset. Diabetologia 2023; 66: 2387-2388
    CrossrefPubMedSuche in Google Scholar
  • 47 Steck AK, Larsson HE, Liu X. et al. Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls. Pediatr Diabetes 2017; 18: 794-802
    CrossrefPubMedSuche in Google Scholar
  • 48 Steffes MW, Sibley S, Jackson M. et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832-836
    CrossrefPubMedSuche in Google Scholar
  • 49 Lachin JM, McGee P, Palmer JP. et al. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014; 63: 739-748
    CrossrefPubMedSuche in Google Scholar
  • 50 Gubitosi-Klug RA, Braffett BH, Hitt S. et al. Residual beta cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. J Clin Invest 2021; 131
    CrossrefPubMedSuche in Google Scholar
  • 51 Forlenza GP, McVean J, Beck RW. et al. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2023; 329: 990-999
    CrossrefPubMedSuche in Google Scholar
  • 52 Hummel M, Ziegler AG, Roth R. Psychological impact of childhood islet autoantibody testing in families participating in the BABYDIAB study. Diabet Med 2004; 21: 324-328
    CrossrefPubMedSuche in Google Scholar
  • 53 Kordonouri O, Lange K, Boettcher I. et al. New approach for detection of LDL-hypercholesterolemia in the pediatric population: The Fr1dolin-Trial in Lower Saxony, Germany. Atherosclerosis 2019; 280: 85-91
    CrossrefPubMedSuche in Google Scholar
  • 54 Müller I, Galuschka L, Marquardt E. et al. Wohlbefinden von Eltern der Kinder aus der Fr1dolin-Früherkennungsstudie in Niedersachsen/Hamburg. Diabetol Stoffwechs 2021; 16: S59
    Thieme ConnectPubMedSuche in Google Scholar
  • 55 Herold KC, Bundy BN, Long SA. et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med 2019; 381: 603-613
    CrossrefPubMedSuche in Google Scholar
  • 56 Sims EK, Bundy BN, Stier K. et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 2021; 13: eabc8980
    CrossrefPubMedSuche in Google Scholar
  • 57 Hagopian W, Ferry RJ, Sherry N. et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes 2013; 62: 3901-3908
    CrossrefPubMedSuche in Google Scholar
  • 58 Herold KC, Gitelman SE, Ehlers MR. et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013; 62: 3766-3774
    CrossrefPubMedSuche in Google Scholar
  • 59 Herold KC, Gitelman SE, Willi SM. et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013; 56: 391-400
    CrossrefPubMedSuche in Google Scholar
  • 60 Perdigoto AL, Preston-Hurlburt P, Clark P. et al. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 2019; 62: 655-664
    CrossrefPubMedSuche in Google Scholar
  • 61 Ramos EL, Dayan CM, Chatenoud L. et al Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. N Engl J Med 2023; (Epub Oct 18)
    CrossrefPubMedSuche in Google Scholar
  • 62 Skyler JS, Krischer JP, Wolfsdorf J. et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial—Type 1. Diabetes Care 2005; 28: 1068-1076
    CrossrefPubMedSuche in Google Scholar
  • 63 Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group. Krischer JP, Schatz DA, Bundy B. et al. Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients with Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2017; 318: 1891-1902
    CrossrefPubMedSuche in Google Scholar
  • 64 Libman I, Bingley PJ, Becker D. et al. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care 2023; 46: 2035-2043
    CrossrefPubMedSuche in Google Scholar
  • 65 Russell WE, Bundy BN, Anderson MS. et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023; 46: 1005-1013
    CrossrefPubMedSuche in Google Scholar
  • 66 Lange K. Früherkennungsuntersuchungen zum Typ-1-Diabetes aus psychologischer Sicht. Diabetologe 2018; 14: 250-256
    CrossrefPubMedSuche in Google Scholar
  • 67 Karl FM, Winkler C, Ziegler AG. et al. Costs of Public Health Screening of Children for Presymptomatic Type 1 Diabetes in Bavaria, Germany. Diabetes Care 2022; 45: 837-844
    CrossrefPubMedSuche in Google Scholar
  • 68 Wilson JM, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968. (Public Health Paper Number 34.)
    Suche in Google Scholar
  • 69 Brindle P, Fahey T. Primary prevention of coronary heart disease. BMJ 2002; 325: 56-57
    CrossrefPubMedSuche in Google Scholar
  • 70 Hendriks AEJ, Marcovecchio ML, Besser REJ. et al. Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes. Diabetes Metab Res Rev 2024; 40: e3777
    CrossrefPubMedSuche in Google Scholar